• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [551 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2016 National Institute for Health and Care Excellence (NICE) Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. NICE technology appraisal guidance 395
2016 NIHR Health Technology Assessment programme The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
2016 National Institute for Health and Care Excellence (NICE) Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. NICE technology appraisal guidance 402
2016 National Institute for Health and Care Excellence (NICE) Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016 National Institute for Health and Care Excellence (NICE) Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 406
2016 National Institute for Health and Care Excellence (NICE) Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 411
2016 Institute for Clinical Effectiveness and Health Policy (IECS) Nivolumab for the treatment of non-small cell lung cancer
2016 Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care times for the main cancer sites: colon/rectum, lung, breast and prostate]
2016 National Institute for Health and Care Excellence (NICE) Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 422
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab - Addendum to Commission A15-32]
2016 NIHR Horizon Scanning Centre (NIHR HSC) Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for advanced BRAF mutated non-small cell lung cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Dacomitinib for locally advanced or metastatic EGFR positive non-small cell lung cancer – first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Crizotinib (Xalkori) for ALK-positive, locally advanced or metastatic, non-small cell lung cancer — first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) with paclitaxel and carboplatin for stage IV or recurrent non-small cell lung cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) Rociletinib for advanced or recurrent non-small cell lung cancer with the EGFR T790M mutation
2015 NIHR Horizon Scanning Centre (NIHR HSC) Selumetinib for KRAS mutation-positive advanced non-small cell lung cancer – second line
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]
2015 NIHR Horizon Scanning Centre (NIHR HSC) Texture analysis of Radiological images (TexRAD) for lung cancer assessment
2015 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer
2015 Andalusian Health Technology Assessment Area (AETSA) Active immunotherapy for lung cancer. Systematic review.
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 National Institute for Health and Care Excellence (NICE) Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. NICE technology appraisal guidance 347
2015 New Zealand National Health Committee (NHC) Epidermal growth factor receptor gene mutation analysis testing assessment
2015 National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 362
2015 NIHR Horizon Scanning Centre (NIHR HSC) AZD9291 for locally advanced or metastatic, EGFR and T790M mutation positive non-small cell lung cancer – second line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) for small cell lung cancer – first line, in combination with etoposide and platinum therapy
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 HAYES, Inc. Cryoablation for treatment of non-small cell lung cancer
2015 NIHR Horizon Scanning Centre (NIHR HSC) Alectinib for advanced ALK-positive, non-small cell lung cancer – first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Alectinib for locally advanced or metastatic ALK-positive, non-small cell lung cancer following failure of crizotinib
2015 NIHR Horizon Scanning Centre (NIHR HSC) Atezolizumab for locally advanced or metastatic non-small cell lung cancer – second line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Bavituximab for advanced non-small cell lung cancer – second line in combination with docetaxel
2015 NIHR Horizon Scanning Centre (NIHR HSC) Bevacizumab (Avastin) with erlotinib (Tarceva) for EGFR positive, advanced or metastatic non-small cell lung cancer – first line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for metastatic BRAF V600E positive non-small cell lung cancer
2015 NIHR Health Technology Assessment programme LDK378 for previously treated anaplastic-lymphoma-kinase-positive non-small-cell lung cancer [ID729]
2014 Health Council of the Netherlands Gezondheidsraad (GR) Dimethyl sulphate. Health-based calculated occupational cancer risk values
2014 NIHR Health Technology Assessment programme Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer
2014 NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab (Cyramza) in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer – second line
2014 NIHR Horizon Scanning Centre (NIHR HSC) Necitumumab in combination with gemcitabine and cisplatin for advanced and metastatic non-small cell lung cancer – first line
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afatinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palliation vs. curation - an attempt to clarify terms]
2014 Haute Autorite de sante (HAS) [Endobronchial ultrasound-guided transbronchial needle aspiration]
2014 National Institute for Health and Care Excellence (NICE) Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 310
2014 Institute of Health Economics (IHE) Low dose computed tomography for the screening of lung cancer in adults
2014 HAYES, Inc. VeriStrat test to predict response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)
2014 HAYES, Inc. ERCC1 expression analysis in Non-Small Cell Lung Cancer (NSCLC)
2014 HAYES, Inc. PTEN gene expression testing in Non-Small Cell Lung Cancer (NSCLC)
2014 Institut national d'excellence en sante et en services sociaux (INESSS) [Lung cancer: investigation, treatment and follow-up algorithms]
2014 Medical Services Advisory Committee (MSAC) Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)
2014 HAYES, Inc. Virtual bronchoscopic navigation for evaluation of peripheral pulmonary lesions
2014 NIHR Health Technology Assessment programme Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis
2014 HAYES, Inc. Computed tomography-guided percutaneous microwave ablation for lung nodules
2013 NIHR Health Technology Assessment programme Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours
2013 NIHR Horizon Scanning Centre (NIHR HSC) Gefitinib (Iressa) with chemotherapy for EGFR-positive non-small cell lung cancer – second line
2013 NIHR Horizon Scanning Centre (NIHR HSC) Onartuzumab for metastatic Met positive non-small cell lung cancer
2013 NIHR Horizon Scanning Centre (NIHR HSC) MK-3475 for advanced or recurrent PD-L1 positive non-small cell lung cancer – second line
2013 NIHR Horizon Scanning Centre (NIHR HSC) LDK378 for ALK-activated advanced non-small cell lung cancer – second and subsequent lines
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 NIHR Horizon Scanning Centre (NIHR HSC) Anamorelin for anorexia-cachexia in advanced non-small cell lung cancer
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-15 Crizotinib]
2013 Medical Services Advisory Committee (MSAC) Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib
2013 Agency for Healthcare Research and Quality (AHRQ) Screening for lung cancer: systematic review to update the U.S. Preventive Services Task Force Recommendation
2013 Medical Services Advisory Committee (MSAC) Epidermal Growth Factor Receptor (EGFR) testing to determine eligibility for afatinib treatment in patients with locally advanced or metastatic non-small-cell lung cancer.
2013 Medical Services Advisory Committee (MSAC) Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent)
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Afatinib (Gilotrif®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)
2013 Agency for Healthcare Research and Quality (AHRQ) Local nonsurgical therapies for stage 1 and symptomatic obstructive non–small-cell lung cancer
2013 National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating primary lung cancer and metastases in the lung. NICE interventional procedures guidance 441
2013 NIHR Horizon Scanning Centre (NIHR HSC) Eribulin mesilate (Halaven) for advanced non-small cell lung cancer – third line
2013 National Institute for Health and Care Excellence (NICE) EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. NICE diagnostics guidance 9
2013 Malaysian Health Technology Assessment (MaHTAS) Epidermal Growth Factor Receptor (EGFR) mutation test for patients with Non-Small Cell Lung Cancer (NSCLC)
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)
2013 NIHR Health Technology Assessment programme Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small cell lung cancer
2013 NIHR Horizon Scanning Centre (NIHR HSC) Nivolumab for non-small cell lung cancer – second line
2013 Belgian Health Care Knowledge Centre (KCE) Non-small cell and small cell lung cancer: diagnosis, treatment and follow-up
2013 HAYES, Inc. Low-dose helical (spiral) computed tomography for lung cancer screening
2013 NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation
2013 HAYES, Inc. Nanoparticle albumin-bound paclitaxel for non-small cell lung cancer
2013 NIHR Health Technology Assessment programme Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
2012 HAYES, Inc. Anaplastic lymphoma kinase (ALK) gene rearrangement testing in non-small cell lung cancer (NSCLC)
2012 Institute for Clinical Effectiveness and Health Policy (IECS) [Photodynamic therapy for lung cancer]
2012 Andalusian Health Technology Assessment Area (AETSA) [MicroRNAs as a diagnostic tool for lung cancer]
2012 NIHR Horizon Scanning Centre (NIHR HSC) Liposomal cisplatin (Nanoplatin) for advanced non-small cell lung cancer – first line
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Erlotinib for the 1st -line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations
2012 Medical Services Advisory Committee (MSAC) Gefitinib first line testing for mutations of epidermal growth factor receptor (EGFR) in patients with metastatic non-small cell lung cancer (NSCLC)
2012 NIHR Horizon Scanning Centre (NIHR HSC) GSK1572932A for non-small cell lung cancer (NSCLC): melanoma-associated antigen 3 (MAGE-A3) positive; stage IB, II or IIIA – adjuvant therapy
2012 Medical Services Advisory Committee (MSAC) Robotic image-guided stereotactic precise beam radiosurgery and radiotherapy for prostate and lung
2012 Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Criteria for appropriate use of FDG-PET in lung cancer
2012 HAYES, Inc. KRAS sequence variant analysis for predicting response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of non-small cell lung cancer (NSCLC)
2012 NIHR Horizon Scanning Centre (NIHR HSC) Iniparib (Tivolza) in combination with gemcitabine and carboplatin for stage IV squamous non-small cell lung cancer
2012 HAYES, Inc. Epidermal Growth Factor Receptor (EGFR) sequence variant analysis for predicting response to Non-Small Cell Lung Cancer (NSCLC) drug therapy
2012 HAYES, Inc. EarlyCDT-lung risk assessment test (Oncimmune [USA] LLC)
2012 Scottish Health Technologies Group (SHTG) The clinical and cost-effectiveness of radiofrequency ablation for lung cancer
2012 HAYES, Inc. VeriStrat® Test to predict response to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)
2012 NIHR Horizon Scanning Centre (NIHR HSC) Dacomitinib for advanced or metastatic non-small cell lung cancer – second or third line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer – first line
2012 National Institute for Health and Care Excellence (NICE) Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258
2012 NIHR Health Technology Assessment programme Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small-cell lung cancer